269 related articles for article (PubMed ID: 28042031)
1. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.
Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q
Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031
[TBL] [Abstract][Full Text] [Related]
2. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression.
Chen L; Qiu X; Wang X; He J
Biochem Biophys Res Commun; 2017 May; 487(1):8-14. PubMed ID: 28302482
[TBL] [Abstract][Full Text] [Related]
3. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T
Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470
[TBL] [Abstract][Full Text] [Related]
4. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
Chen MC; Hsu HH; Chu YY; Cheng SF; Shen CY; Lin YJ; Chen RJ; Viswanadha VP; Lin YM; Huang CY
Environ Toxicol; 2018 May; 33(5):587-593. PubMed ID: 29436100
[TBL] [Abstract][Full Text] [Related]
5. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
8. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
10. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
[TBL] [Abstract][Full Text] [Related]
11. Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression.
Huang WS; Lin CT; Chen CN; Chang SF; Chang HI; Lee KC
J Cell Biochem; 2018 Aug; 119(8):6943-6952. PubMed ID: 29737584
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
14. Astragaloside IV Induced miR-134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW-480.
Ye Q; Su L; Chen D; Zheng W; Liu Y
Cell Physiol Biochem; 2017; 43(4):1617-1626. PubMed ID: 29041002
[TBL] [Abstract][Full Text] [Related]
15. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.
Ruiz de Porras V; Bystrup S; Martínez-Cardús A; Pluvinet R; Sumoy L; Howells L; James MI; Iwuji C; Manzano JL; Layos L; Bugés C; Abad A; Martínez-Balibrea E
Sci Rep; 2016 Apr; 6():24675. PubMed ID: 27091625
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
[TBL] [Abstract][Full Text] [Related]
17. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
Zhang Z; Shen C; Zhou F; Zhang Y
Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
[TBL] [Abstract][Full Text] [Related]
18. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
19. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
[TBL] [Abstract][Full Text] [Related]
20. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
